Literature DB >> 22684563

Mechanisms of prostate atrophy after LHRH antagonist cetrorelix injection: an experimental study in a rat model of benign prostatic hyperplasia.

Dong Yang1, Teng Hou2, Xiong Yang1, Yan Ma1, Longwang Wang1, Bing Li3.   

Abstract

In the present study, we investigated the roles of TGF-β signaling pathway in a rat benign prostatic hyperplasia (BPH) model treated with cetrorelix. TGF-β1 and c-Myc expression were measured by qRT-PCR and Western blotting in the proximal and distal region of ventral prostatic lobes, respectively. We observed that treatment with cetrorelix led to a significant reduction of ventral prostate weight in a dose-dependent manner. In the proximal region, after cetrorelix treatment, the expression of TGF-β1 was dramatically increased (P<0.05), while the expression of c-Myc was significantly decreased (P<0.05). In comparison with the control group, the cetrorelix groups had more TUNEL-positive cells. Our findings strongly suggest that the TGF-β signaling pathway may be one of the major causes responsible for prostate volume reduction in BPH rats after cetrorelix treatment.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22684563     DOI： 10.1007/s11596-012-0067-x

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN： 1672-0733


  45 in total

1.  Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology.

Authors:  Oscar M Pello; Maria De Pizzol; Massimiliano Mirolo; Laura Soucek; Luca Zammataro; Angelo Amabile; Andrea Doni; Manuela Nebuloni; Lamorna B Swigart; Gerard I Evan; Alberto Mantovani; Massimo Locati
Journal:  Blood       Date:  2011-11-08       Impact factor: 22.113

Review 2.  Regulation of prostatic growth and function by peptide growth factors.

Authors:  Z Culig; A Hobisch; M V Cronauer; C Radmayr; A Hittmair; J Zhang; M Thurnher; G Bartsch; H Klocker
Journal:  Prostate       Date:  1996-06       Impact factor: 4.104

Review 3.  Benign prostatic hyperplasia: age-related tissue-remodeling.

Authors:  Gerold Untergasser; Stephan Madersbacher; Peter Berger
Journal:  Exp Gerontol       Date:  2005-01-22       Impact factor: 4.032

4.  Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.

Authors:  Gero Kramer; Georg E Steiner; Alessandra Handisurya; Ursula Stix; Andrea Haitel; Birgit Knerer; Alois Gessl; Chung Lee; Michael Marberger
Journal:  Prostate       Date:  2002-06-01       Impact factor: 4.104

5.  The clinical implications of the difference between castration, gonadotrophin releasing-hormone (GnRH) antagonists and agonist treatment on the morphology and expression of GnRH receptors in the rat ventral prostate.

Authors:  A Tieva; A Bergh; J-E Damber
Journal:  BJU Int       Date:  2003-02       Impact factor: 5.588

6.  Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.

Authors:  Bernadett Rozsa; Mehrdad Nadji; Andrew V Schally; Balazs Dezso; Tibor Flasko; Gyorgy Toth; Melinda Mile; Norman L Block; Gabor Halmos
Journal:  Prostate       Date:  2010-09-21       Impact factor: 4.104

7.  Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-beta 1 and its type-I and type-II receptors.

Authors:  M Landström; S Eklöv; P Colosetti; S Nilsson; J E Damber; A Bergh; K Funa
Journal:  Int J Cancer       Date:  1996-08-07       Impact factor: 7.396

8.  LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.

Authors:  Ferenc G Rick; Andrew V Schally; Norman L Block; Gabor Halmos; Roberto Perez; Jesus B Fernandez; Irving Vidaurre; Luca Szalontay
Journal:  Prostate       Date:  2010-10-13       Impact factor: 4.104

Review 9.  Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes.

Authors:  Andrei L Gartel; Ksenya Shchors
Journal:  Exp Cell Res       Date:  2003-02-01       Impact factor: 3.905

10.  Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.

Authors:  A M Comaru-Schally; W Brannan; A V Schally; M Colcolough; M Monga
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958
View more
  2 in total

1.  Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.

Authors:  Ferenc G Rick; Andrew Abi-Chaker; Luca Szalontay; Roberto Perez; Miklos Jaszberenyi; Arumugam R Jayakumar; Nagarajarao Shamaladevi; Karoly Szepeshazi; Irving Vidaurre; Gabor Halmos; Awtar Krishan; Norman L Block; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

2.  In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth.

Authors:  Monica Sakai; Daniel B Martinez-Arguelles; Nathan H Patterson; Pierre Chaurand; Vassilios Papadopoulos
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.